Advertisement

Annals of Clinical Psychiatry

, Volume 10, Issue 1, pp 31–33 | Cite as

Risperidone-Induced Galactorrhea Associated with a Prolactin Elevation

  • Anand Popli
  • Sanjay Gupta
  • Sunil R. Rangwani
Article
  • 23 Downloads

Abstract

We report on the occurrence of galactorrhea associated with a prolactin elevation within weeks of treatment with risperidone. One of our patients was switched to a typical antipsychotic, with an improvement in the galactorrhea. The other patient was continued on risperidone due to a robust response, while her galactorrhea was partially treated with bromocriptine. The mechanism of prolactin elevation with risperidone is unclear. These cases suggest the need for further studies.

Risperidone galactorrhea side effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Marder SR, Meibach RC: Risperidone in the treatment of Schizophrenia. Am J Psychiatry 1994; 151:825–835Google Scholar
  2. 2.
    Gupta S, Black DW, Smith DA: Risperidone: Review of its pharmacology, and therapeutic use in schizophrenia. Ann Clin Psychiatry 1994; 6:173–180Google Scholar
  3. 3.
    Bersani G, Grisfini A, Marini S, Pasini A, Valducci M, Ciani M: Neuroleptic-induced extrapyramidal side effects: Clinical perspectives with ritanserin (R 55 667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 1986; 40:492–499Google Scholar
  4. 4.
    Casey DE: What makes a neuroleptic atypical? In: Meltzer HY, ed. Novel Antipsychotic Drugs. New York, Raven Press; 1992:241–251Google Scholar
  5. 5.
    Kerwin RW: The new atypical antipsychotics: A lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry 1994; 164:141–148Google Scholar
  6. 6.
    Casey DE: Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 1989; 99:S47-S53Google Scholar
  7. 7.
    Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS: Effect of clozapine on human serum prolactin levels. Am J Psychiatry 1979; 136:1550–1555Google Scholar
  8. 8.
    Schotte A, Janssen PFM, Gommeren, Luyten WHML, Gompel PV, Lesage AS, Loore KD, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 1996; 124:57–73Google Scholar
  9. 9.
    Dickinson RA, Dalby JT, Williams R, Edwards AL: Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry 1995; 157:1102–1103Google Scholar
  10. 10.
    Hardan A, Johnson K, Johnson C, Hrecznyj B: Case Study: Risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996; 35:1551–1556Google Scholar
  11. 11.
    Frantz AG, Kleinberg DL, Noel GL: Studies on prolactin in man. Rec Prog Horm Res 1972; 28:527–598Google Scholar
  12. 12.
    Adams JB: Human breast cancer: Concerned role of diet, prolactin and adrenal C19–5-steroids. Int J Cancer 1992; 50:854–858Google Scholar
  13. 13.
    Gold EB, Bush T, Chee E: Risk factors for secondary amenorrhea and galactorrhea. Int J Fertil Menopausal Stud 1994; 39(3):177–184Google Scholar

Copyright information

© American Academy of Clinical Psychiatrists 1998

Authors and Affiliations

  • Anand Popli
    • 1
  • Sanjay Gupta
    • 2
  • Sunil R. Rangwani
    • 3
  1. 1.Porter Starke Counseling Centers & Porter Memorial HospitalValparaiso
  2. 2.Department of PsychiatryOlean General Hospital West, and Research & Education Division of Psychiatric Network, Olean, and Department of Psychiatry, SUNY Health Science Center at SyracuseSyracuse
  3. 3.Department of PsychiatryGratiot Community HospitalAlma

Personalised recommendations